Zinc and Beta-Glucan for Immunity: What the Dose on Your Label Actually Does

Zinc and beta-glucan both show up on immune-support labels constantly. The trial evidence for each is genuinely different in strength — and knowing the difference changes what you should actually expect.

This formula includes zinc at 136% RDI (15mg) and yeast-derived 1,3/1,6 beta-glucan at 36mg. Both ingredients have real clinical trial data behind them. Neither is a myth. But the details of dosing and what the trials actually measured matter more than the ingredient names on their own.

What the research actually shows

Zinc's evidence for the common cold is genuinely strong, but dose-dependent in a way worth understanding. A 2013 Cochrane systematic review by Singh and Das pooled 16 therapeutic trials (1,387 participants) and found zinc intake was associated with a significant reduction in cold duration — by just over a day on average — when administered within 24 hours of symptom onset. The review specifically notes that benefit was demonstrated at doses of 75mg per day or higher, using zinc lozenges specifically, not general zinc supplementation at any dose or format.

This product's 15mg dose is well below that 75mg therapeutic threshold used in the trials showing cold-duration benefit. That's an important distinction: 15mg daily supports normal immune function and covers a genuine nutritional requirement — zinc deficiency does impair immune response — but it's not the same intervention as the acute, high-dose lozenge protocol the Cochrane review evaluated for actively shortening a cold once symptoms start.

The beta-glucan evidence, on the specific 1,3/1,6 form used in this product, comes from two separate randomised controlled trials. A 2017 double-blind placebo-controlled trial by Fuller et al., published in Nutrition, tested 250mg daily of yeast-derived beta-1,3/1,6 glucan in older adults over 90 days during winter. There was a strong trend toward fewer symptom days, and lab measures showed a genuine shift in innate immune markers — increased interferon-gamma response — though the reduction in confirmed infections didn't reach statistical significance in this sample size.

A larger 2018 double-blind randomised trial by Dharsono et al., published in the Journal of the American College of Nutrition, tested 900mg daily in 299 adults prone to frequent colds. The incidence of colds wasn't significantly different from placebo, but the severity of physical symptoms during the first week of an infection was significantly lower in the beta-glucan group across every time point measured, alongside a modest reduction in blood pressure.

What this means for you

The honest picture: neither ingredient at these doses is likely to prevent you from catching a cold. What the evidence supports is different and more modest — covering a genuine zinc requirement that supports baseline immune function, plus a beta-glucan dose in a similar range to trials showing reduced symptom severity once you do get sick, rather than reduced incidence.

If you specifically want the acute cold-shortening effect the Cochrane zinc review documents, that requires a much higher dose (75mg+) taken as a lozenge within 24 hours of symptom onset — a different use case from daily baseline supplementation like this product provides.

The biotype angle

Mesomorphs and endomorphs in heavy training loads have elevated zinc losses through sweat, making the baseline 15mg dose more relevant as a genuine gap-filler rather than an optional extra.

Ectomorphs with lower overall food intake are also at higher risk of falling short on zinc from diet alone, since zinc-dense foods (red meat, shellfish, legumes) aren't always eaten in large volumes by this biotype.

Anyone in a high-exposure environment during winter — shift workers, people in close contact with the public, parents of young children — may find the beta-glucan symptom-severity data the most practically relevant piece of this formula, even without a guaranteed reduction in how often you get sick.

Want a training and nutrition program built around your actual biotype — not a generic plan?
→ milenium.com.au/pages/biofit-training

References:
1. Singh M, Das RR. Zinc for the common cold. Cochrane Database of Systematic Reviews, 2013. DOI: 10.1002/14651858.CD001364.pub4
2. Fuller R et al. Yeast-derived beta-1,3/1,6 glucan, upper respiratory tract infection and innate immunity in older adults. Nutrition, 2017. DOI: 10.1016/j.nut.2017.03.003
3. Dharsono T et al. Effects of Yeast (1,3)-(1,6)-Beta-Glucan on Severity of Upper Respiratory Tract Infections. Journal of the American College of Nutrition, 2018. DOI: 10.1080/07315724.2018.1478339